{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"710","value":"1850"},{"groupId":"OG001","spread":"483","value":"2060"},{"groupId":"OG002","spread":"1140","value":"2340"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"}],"units":"Participants"}],"description":"AUC(0-48)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-48).","dispersionType":"Standard Deviation","groups":[{"description":"Single oral dose of bosutinib 400 mg on Day 1 and then bosutinib 400 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG000","title":"Bosutinib 400 mg (Part 1)"},{"description":"Single oral dose of bosutinib 500 mg on Day 1 and then bosutinib 500 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study.","id":"OG001","title":"Bosutinib 500 mg (Part 1)"},{"description":"Single oral dose of bosutinib 600 mg on Day 1 and then bosutinib 600 mg orally once daily continuously from Day 3 up to Week 4. All participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study. Eleven participants who completed treatment in Part 1 were continued in CP2L-CML Part 2 of the study and 1 participant was continued in AP-CML Part 2 of the study.","id":"OG002","title":"Bosutinib 600 mg (Part 1)"}],"paramType":"MEAN","populationDescription":"Evaluable population included all enrolled participants who received at least 1 dose of study medication and had an adequate baseline efficacy assessment.","reportingStatus":"POSTED","timeFrame":"0 (pre-dose), 1, 2, 3, 4, 6, 8, 24, 48 hours post-dose on Day 1","title":"Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC(0-48)] - Part 1","type":"PRIMARY","unitOfMeasure":"ng*hr/mL"}